Zila Retains William Blair & Company as Its Financial Advisor

Business Wire, Oct 1, 2008

PHOENIX -- Zila, Inc. (NASDAQ:ZILAD) today announced that it has retained investment bank William Blair & Company to assist it in exploring strategic business opportunities.

"In recent months, we have established a solid foundation upon which to grow our business by reducing expenses, restructuring our operations and adding new international markets for ViziLite([R]) Plus," said David Bethune, chairman and chief executive officer of Zila. "The engagement of William Blair is an important element in our plan to shore up our capital structure and further evaluate opportunities for growth."

About Zila, Inc.

Zila, Inc., is a fully integrated oral diagnostic company dedicated to the prevention, detection and treatment of oral cancer and periodontal disease. ViziLite([R]) Plus with TBlue([R]), the company's flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer. In addition, Zila designs, manufactures and markets a suite of proprietary products sold exclusively and directly to dental professionals for periodontal disease, including the Rotadent([R]) Professional Powered Brush, the Pro-Select Platinum([R]) ultrasonic scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely affect revenue, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2007 and Form 10-Q for the quarter ended April 30, 2008.

For more information about the company and its products, please visit www.zila.com.